Ekso Bionics and Vodafone Receive 2016 HealthTechZone Telehealth Award
RICHMOND, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton company, announced today that the company received a 2016 Telehealth Award from HealthTechZone.com, a leading healthcare technology news source that is a subsidiary of Technology Marketing Corporation (TMC). The award, which recognizes vendors with proven success in improving health delivery and management, was granted to the EksoGT™ exoskeleton connected with Vodafone IoT technology.
Ekso Bionics has developed the EksoPulse™ technology, which is an advanced cloud-based platform that uniquely allows physical therapists (PTs) to personalize patient care. EksoPulse, which is now incorporated into the EksoGT exoskeletons, allows PTs to not only capture patient progress during sessions, but to store the therapeutic data in a shared system, to synchronize that data with cellular technology in order to track changes in patient performance, and to then make customized adjustments to care plans.
“We are honored to receive this award together with our partner, Vodafone,” shared Thomas Looby, Ekso Bionics’ president and chief executive officer. “Ekso Bionics is at the forefront of exoskeleton technology development - not only is the EksoGT the first exoskeleton approved for stroke and spinal cord injuries above T4, it is now the only device to offer a truly personalized solution for patients rehabilitating from these life-changing injuries,” Looby added.
Vodafone's network and global Internet of Things (IoT) SIM – embedded in each EksoGT exoskeleton suit – ensures reliable communications for diagnostics by capturing and sharing patient data with clinicians. With Vodafone IoT technology, clinicians can now measure how patients are progressing in real time.
“We are very pleased to be recognized by the HealthTechZone Telehealth Awards for our collaboration with Ekso Bionics,” said Ivo Rook, Vodafone’s Group Head of IoT. “Vodafone’s Internet of Things is enabling all types of medical devices to be used anywhere in the world, which is directly affecting the care that patients are receiving. Through our partnership with Ekso Bionics, we are helping to make a positive impact on stroke and spinal cord injury rehabilitation.”
“It is my pleasure to recognize the EksoGT, an innovative solution that earned Ekso Bionics and Vodafone the 2016 Telehealth Award,” said Rich Tehrani, CEO, TMC. “I look forward to seeing more innovation from these companies in the future.”
For more information, please visit www.tmcnet.com.
Global buyers rely on TMC’s content-driven marketplaces to make purchase decisions and navigate markets. This presents branding, thought leadership and lead generation opportunities for vendors/sellers.
- Unique, turnkey Online Communities boost search results, establish market validation, elevate brands and thought leadership, while minimizing ad-blocking.
- Custom Lead Programs uncover sales opportunities and build databases.
- In-Person and Online Events boost brands, enhance thought leadership and generate leads.
- Publications, Display Advertising and Newsletters bolster brand reputations.
- Custom Content provides expertly ghost-crafted blogs, press releases, articles and marketing collateral to help with SEO, branding, and overall marketing efforts.
- Comprehensive Event and Road Show Management Services help companies meet potential clients and generate leads face-to-face.
For more information about TMC and to learn how we can help you reach your marketing goals, please visit www.tmcnet.com.
About Ekso Bionics®
Ekso Bionics is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical, industrial and defense applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe, to providing research for the advancement of R&D projects intended to benefit U.S. defense capabilities. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.
Ekso Bionics Media Contact: Carrie Yamond 917-371-2320 firstname.lastname@example.org Ekso Bionics Investor Contact: Debbie Kaster 415-937-5403 email@example.com TMC Contact: Stephanie Thompson, Manager 203-852-6800, ext. 139 firstname.lastname@example.org
Released April 7, 2017